Southern Asia: Medicaments Containing Insulin Market 2024

Medicaments Containing Insulin Market Size in Southern Asia

The South Asian medicaments containing insulin market rose sharply to $X in 2021, surging by 5% against the previous year. Overall, consumption showed strong growth. Over the period under review, the market hit record highs in 2021 and is expected to retain growth in the immediate term.

Medicaments Containing Insulin Production in Southern Asia

In value terms, medicaments containing insulin production amounted to $X in 2021 estimated in export price. Overall, production saw a relatively flat trend pattern. The growth pace was the most rapid in 2016 when the production volume increased by 11%. As a result, production attained the peak level of $X. From 2017 to 2021, production growth failed to regain momentum.

Medicaments Containing Insulin Exports

Exports in Southern Asia

In 2021, medicaments containing insulin exports in Southern Asia shrank dramatically to X tons, reducing by -75.1% on the year before. Over the period under review, exports showed a sharp shrinkage. The growth pace was the most rapid in 2020 when exports increased by 58%. The volume of export peaked at X tons in 2013; however, from 2014 to 2021, the exports stood at a somewhat lower figure.

In value terms, medicaments containing insulin exports reduced sharply to $X in 2021. Overall, exports faced a dramatic shrinkage. The pace of growth was the most pronounced in 2013 when exports increased by 13% against the previous year. As a result, the exports attained the peak of $X. From 2014 to 2021, the growth of the exports failed to regain momentum.

Exports by Country

India dominates exports structure, amounting to X tons, which was near 94% of total exports in 2021. It was distantly followed by Pakistan (X kg), comprising a 6.1% share of total exports.

Exports from India decreased at an average annual rate of -35.1% from 2012 to 2021. Pakistan (-29.5%) illustrated a downward trend over the same period. While the share of Pakistan (+3.1 p.p.) increased significantly in terms of the total exports from 2012-2021, the share of India (-3.1 p.p.) displayed negative dynamics.

In value terms, the largest medicaments containing insulin supplying countries in Southern Asia were India ($X) and Pakistan ($X).

In terms of the main exporting countries, Pakistan, with a CAGR of -27.7%, saw the highest growth rate of the value of exports, over the period under review.

Export Prices by Country

In 2021, the export price in Southern Asia amounted to $X per ton, rising by 17% against the previous year. In general, the export price, however, faced a deep slump. The most prominent rate of growth was recorded in 2015 when the export price increased by 32%. The level of export peaked at $X per ton in 2012; however, from 2013 to 2021, the export prices failed to regain momentum.

There were significant differences in the average prices amongst the major exporting countries. In 2021, amid the top suppliers, the country with the highest price was Pakistan ($X per ton), while India stood at $X per ton.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by Pakistan (+2.6%).

Medicaments Containing Insulin Imports

Imports in Southern Asia

In 2021, purchases abroad of medicaments containing insulin but not antibiotics increased by 47% to X tons, rising for the second year in a row after two years of decline. Over the period under review, imports, however, recorded a relatively flat trend pattern. The growth pace was the most rapid in 2015 when imports increased by 84% against the previous year. Over the period under review, imports hit record highs at X tons in 2013; however, from 2014 to 2021, imports stood at a somewhat lower figure.

In value terms, medicaments containing insulin imports soared to $X in 2021. Overall, imports, however, saw a relatively flat trend pattern. The pace of growth appeared the most rapid in 2015 when imports increased by 197%. The level of import peaked at $X in 2013; however, from 2014 to 2021, imports stood at a somewhat lower figure.

Imports by Country

In 2021, India (X tons), Pakistan (X tons) and Sri Lanka (X tons) was the major importer of medicaments containing insulin but not antibiotics in Southern Asia, committing 90% of total import. It was distantly followed by Bangladesh (X kg), mixing up a 7.7% share of total imports. Nepal (X kg) followed a long way behind the leaders.

From 2012 to 2021, the biggest increases were recorded for Sri Lanka (with a CAGR of +7.1%), while purchases for the other leaders experienced mixed trends in the imports figures.

In value terms, India ($X) constitutes the largest market for imported medicaments containing insulin but not antibiotics in Southern Asia, comprising 67% of total imports. The second position in the ranking was taken by Pakistan ($X), with a 14% share of total imports. It was followed by Bangladesh, with a 14% share.

From 2012 to 2021, the average annual growth rate of value in India amounted to -1.2%. The remaining importing countries recorded the following average annual rates of imports growth: Pakistan (+17.4% per year) and Bangladesh (-2.8% per year).

Import Prices by Country

The import price in Southern Asia stood at $X per ton in 2021, with an increase of 8.5% against the previous year. Over the period under review, the import price saw a relatively flat trend pattern. The pace of growth appeared the most rapid in 2016 an increase of 70%. As a result, import price attained the peak level of $X per ton. From 2017 to 2021, the import prices remained at a lower figure.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was India ($X per ton), while Sri Lanka ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by Pakistan (+17.9%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :